TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

Boehringer Ingelheim

MetabolicOncologyRespiratory
Big Pharma

Boehringer Ingelheim is a major pharmaceutical company focused on Metabolic, Oncology, Respiratory. Key products include PRAXBIND.

1961
Since
42
Drugs
-
Trials
33
Approved (2yr)

Key Drugs

PRAXBIND
idarucizumab
Dabigatran 2 indications · 2015
STIOLTO RESPIMAT
olodaterol hydrochloride
Respiratory
M3 receptor 3 indications · 2015
SYNJARDY XR
empagliflozin
Metabolic
SGLT2 3 indications · 2016
JARDIANCE
empagliflozin
Metabolic
SGLT2 3 indications · 2014
SYNJARDY
empagliflozin
Metabolic
SGLT2 3 indications · 2015

Recent Activity

JASCAYD 2025-12-19
Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
GLYXAMBI 2025-10-24
Labeling
TRIJARDY XR 2025-10-24
Labeling
SYNJARDY XR 2025-10-24
Labeling
JARDIANCE 2025-10-24
Labeling
SYNJARDY 2025-10-24
Labeling
SPEVIGO 2025-10-21
Labeling
CYLTEZO 2025-10-16
Bioequivalence
JASCAYD 2025-10-07
Type 1 - New Molecular Entity
HERNEXEOS 2025-08-08
Type 1 - New Molecular Entity
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 25%
6 drugs Phase 3: 17 Phase 2: 5 Phase 1: 16
Oncology 24%
2 drugs Phase 3: 7 Phase 2: 11 Phase 1: 63
Respiratory 22%
8 drugs Phase 3: 6 Phase 2: 9 Phase 1: 21
Immunology 17%
2 drugs Phase 3: 8 Phase 2: 20 Phase 1: 5
Cardiovascular 12%
3 drugs Phase 3: 9 Phase 2: 3

Pipeline Strength Pro

Loading...

Competitors Pro

Novartis big-pharma
Oncology, Cardiovascular, Immunology, Respiratory
AstraZeneca big-pharma
Oncology, Respiratory, Cardiovascular, Metabolic, Immunology
Merck big-pharma
Oncology, Cardiovascular, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Cardiovascular, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Immunology, Respiratory